Fig. 3

Pharmacological OPA1 Inhibition reduces breast cancer hallmarks in vitro. a Representative brightfield images acquired at the indicated time points of MDA-MB-231, T47D, MCF7 and HS578T cells incubated with MYLS22 (50 μM) or DMSO for 6 h in a scratch-wound assay. Scale bar: 250 μm. b Quantification of cell migration of MDA-MB-231, T47D, MCF7 and HS578T incubated with MYLS22 (50 μM) or DMSO, after 6 h in experiments as in (a). n = 4 independent experiments. ***: p < 0.0001. c Representative brightfield images of MDA-MB-231,T47D, MCF7 and HS578T incubated with MYLS22 (50 μM) or DMSO for 6 h in a Boyden chamber. Scale bar: 200 μm. d Quantification of cell migration of MDA-MB-231,T47D, MCF7 and HS578T, incubated with MYLS22 (50 μM), after 6 h in experiments as in (w). n = 4 independent experiments. ***: p < 0.0001. e Quantification of MYLS22- (50 μM) or DMSO-preincubated MDA-MB-231,T47D, MCF7 and HS578T adhesion on fibronectin for 1 h in presence of MYLS22 (50 μM) or DMSO. n = 4 independent experiments. ***: p < 0.0001. f) Quantification of MDA-MB-231,T47D, MCF7 and HS578Tproliferation incubated with MYLS22 (50 μM) for 24 h and determined by BrdU incorporation. n = 4 independent experiments. ***: p < 0.0001